Total medical devices industry venture financing deals in October 2020 worth $576.77m were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 28.2% over the previous month and a drop of 27.4% when compared with the last 12-month average of $794.31m.
The US held a 54.9% share of the global medical devices industry venture financing deal value that totalled $1.05bn in October 2020.
In terms of deal activity, the US recorded 40 deals during October 2020, marking a decrease of 4.8% over the previous month and a drop of 31.03% over the 12-month average.
The US medical devices industry venture financing deals in October 2020: Top deals
The top five medical devices industry venture financing deals accounted for 53.2% of the overall value during October 2020.
The combined value of the top five medical devices venture financing deals stood at $307m, against the overall value of $576.77m recorded for the month.
The top five medical devices industry deals of October 2020 tracked by GlobalData were:
1) 8VC, Baidu Ventures, Coatue Management, D1 Capital Partners, Lux Capital, Playground Global, Refactor Capital and Sonder Capital’s $100m venture financing of Avail Medsystems
2) The $72m venture financing of Neocis by DFJ Growth Management, Fred Moll, Mithril Capital Management, Norwest Venture Partners, Section 32 and Vivo Capital
3) Asset Management Ventures, Franklin Templeton Investments, Jonathan Fielding, King River Capital, Lightspeed Ventures,Ltd., Olive Tree Capital, SteelSky Ventures and Weili Dai’s $55m venture financing of LARK HEALTH
4) The $45m venture financing of TigerConnect by HealthQuest Capital, Industry Ventures, Invus, Montreux Growth Partners, New Leaf Venture Partners and Norwest Venture Partners
5) Avera Research Institute and Fresenius Medical Care Ventures’ venture financing of Alucent Biomedical for $35m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.